SGLT2 inhibitors are known to reduce diabetic nephropathy risk in patients with type 2 diabetes, but can they also protect against diabetic retinopathy?
New research shows use of the drugs in pregnancy is on the rise, particularly in the United States, and although teratogenic risks appear low, limitations are notable.
Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone.